• BX Home
  • Business of Biotechnology: [Page 12]

Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more

BUSINESS OF BIOTECHNOLOGY

They're perfecting scientific developments that could cure the world's toughest diseases, improve food production, and even yield energy alternatives. This is the exciting world of biotechnology, where young companies fight to make innovative discoveries -- and to find new and innovative ways of funding those innovations.

Business of Biotechnology is part of Business Exchange, suggested by Arlene Weintraub. This topic contains 1,248 news and 4,696 blog items. Read updated news, blogs, and resources about Business of Biotechnology. Find user-submitted articles and reactions on Business of Biotechnology from like-minded professionals.

Most Active

The most active stories in this topic based on user activity.

Sector Close-Up; Stem Cell Stocks on the Movemore

Stem Cell Stocks Sector Close-Up Trading August 7 2009: Aastrom Biosciences, Inc.(NasdaqCM: ASTM) trading up at $0.

Arthritis drugs raise cancer risk in kidsmore

J&J and Amgen are among the companies that will have to revise product labels to reflect the risk.

Generic-drug maker Teva steals market share from Big Pharmamore

The Israeli generic-drug maker has an ambitious growth strategy.

Targeting Angiogenesis in Cancermore

Scientists Breed Mice From Skin Cells in Chinamore

Chinese scientists have bred mice from cells that might offer an alternative to embryonic stem cells, producing the...

3 Top Stocks For Obama’s ‘Honeymoon Period’more

Jim Nelson says savvy investors can make huge profits in the first 100 days of the Obama presidency. Three sectors...

Europe rejects stem cell patentmore

The European Patent Office (EPO) issued its final ruling last week rejecting a much-contested embryonic stem cell...

Biotech drug costs up 8.7 percent: surveymore

LONDON (Reuters) - The cost of specialty biotech drugs increased 8.7 percent last year in the United States, three...

Why Standard Flu Vaccines Won’t Make Investors Rich more

A more recent addition to my transformational technologies portfolio, Medarex, has scored a huge win. The company,...

GE to Obtain Stem Cells From Geron For Research more

Biotech company Geron Corp. agreed to provide stem cells to General Electric Co.'s GE Healthcare for use in tools that...

Wisconsin's economy gets boost from biotechnology | Postcrescent.commore

The crop sprouting on his 150-acre farm in Calumet County is fortified with special traits at the microscopic level,...

FDA Says Amgen Drug Brochure Is Misleadingmore

The biotech giant is taken to task over its advertising brochure for kidney-disease drug Sensipar.

Obama announces agreement with drug companiesmore

President Barack Obama on Monday welcomed the pharmaceutical industry's agreement to help close a gap in Medicare's...

Drug Firms Jockey for Space Onlinemore

A growing number of drug firms are trying their luck with social media tools such as Facebook and Twitter.

100 Best Places to Work in ITmore

These top-rated IT workplaces combine choice benefits with hot technologies and on-target training.

The Fight Over Drug Data Miningmore

Legislators in more than 20 states have questioned whether IMS has a constitutional right to collect prescription data.

FTC: 12-14 yrs too long to protect biotech drugsmore

Generic versions of expensive biotechnology drugs would reduce the amount of money spent on health care in the United...

Biogen chief denies search for investormore

The biotech giant is the subject of merger speculation, but CEO Jim Mullen says no such plans are underway.

Nissen Argues Blockbusters are Deadmore

The Cleveland Clinic doc is urging the federal government to back the creation of novel treatments.

Merck's Heart Failure Failuremore

The failure of a Merck drug to treat acute heart failure in a large clinical trial raises new questions about the...

More musings on pharma megamergersmore

Pfizer Inc.'s (NYSE:PFE) $68 billion acquisition of Wyeth (NYSE:WYE) and Merck & Co.'s (NYSE:MRK) $41 billion bid...

Study gauges effect of drugmakers' ads more

A spike in interest in the drug Zelnorm did little to boost prescriptions.

Bristol-Myers looking to swallow Elan in piecesmore

Shares in Dublin-based biotechnology company Elan Corp. (NYSE:ELN) surged Monday in London after The Wall Street...

Singapore's Economy Begins to Stirmore

The recession hasn't diminished Singapore's zeal to make the city a science and technology hub. The government has...

Loophole Exposes Canadians To Drug Ads Banned In US more

Despite a ban on direct-to-consumer drug advertising in their country, Canadians have been exposed to more than $90...

Topic Feed: Most active content in Business of Biotechnology

Top Sources: Business of Biotechnology

  • investorideas.com
  • bioedgeconsulting.com
  • Biotech Blog
  • bloomberg.com
  • youtube.com
  • News
  • contrarianprofits.com
  • Forbes.com
  • industry.bnet.com
  • Health Beat

Most Active Users in this Topic

see all contributors in Business of Biotechnology

Featured White Papers

Post a Job

Jobs in this Topic

Process Sciences Associate Drug Product Regeneron | Rensselaer, NY
Posted: May 8
SOFTWARE ENGINEER at exciting biotech company! Adaptive Biotechnologies | Seattle, WA
Posted: Apr 19

Report comment contains invalid characters. ()
cancel
Search Cancel